{"groups":[{"description":"Induction Phase Followed by Maintenance Therapy.\n\nPatients received lenalidomide 25 mg orally on days 1-21, dexamethasone 40 mg orally on days on 1-4, and Pegylated Liposomal Doxorubicin (PLD) 40 mg/m\\^2 intravenously on day 1 (reduced to 30 mg/m\\^2 after the initial 29 patients were treated). Cycles were repeated every 28 days.\n\nAt the best response (4-8 cycles of induction), patients could proceed with either high-dose therapy or maintenance with lenalidomide and dexamethasone at the tolerated doses on the same schedule until disease progression.\n\nDd-R: Lenalidomide (Revlimid®) combined with Pegylated Liposomal Doxorubicin (Doxil®) and Dexamethasone (Decadron®) as outlined in the Detailed Description.","id":"FG000","title":"Induction and Maintenance Therapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Withdrew consent during Induction"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Withdrew consent during Maintenance"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"57"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"47"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"57 Eligible participants were enrolled at Moffitt Cancer Center between February 2008 and February 2011."}